Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||SM88||Phase II||Actionable||In a Phase II trial, SM-88 treatment resulted in stable (4/10) or rising (5/10) testosterone levels, and none of the toxicity commonly associated with androgen deprivation therapy in patients with non-metastatic recurrent prostate cancer (J Clin Oncol 36, 2018 (suppl 6S; abstr 175); NCT02796898).||detail...|
|PubMed Id||Reference Title||Details|
|Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.||Full reference...|